RIT with y 90 -ibritumomab tiuxetan in follicular non-hodgkin lymphoma: Evaluation of recent outcomes in a single institution

Background. based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-hodgkin lymphoma (f-nhl) patients treated with 90y-ibritumomab tiuxetan. patients and methods. between 2005 and 2011,56 f-nhl patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre. all patients received 0.3 or 0.4 mci/kg iv (88) of 90y-it; response evaluation was performed 12 weeks after. results. m/f 44.6/55.4,mean age 61.45 years (3085); ecog 0-1 96.9. according to flipi score,distribution were good: 58.5,intermediate: 29.2,and poor: 12.3. previous therapies: >2: 40 (26). orr was 94.6 (53/56). cr: 85.7; cr according to previous disease: relapsed disease: 90 (27/30),refractory disease: 42.85 (3/7),consolidation with cr: 92.85 (13/14),and consolidation with pr: 100 (5/5). global pr and nr were 8.9 (5) and 5.3 (3),respectively. mean os 63.86 months with a mean follow-up time of 57 months (273). mean ttp: 52.65 months (95 ci: 43.8361.48). median os and ttp were not achieved. no hospital submissions or deaths were registered. conclusions. this study confirms the safety and high efficacy of 90y-it in f-nhl patients,rit in early stage of disease could improve outcomes. © 2012 marcio miguel andrade campos et al.